Related Experiment Video

Updated: Jul 7, 2026

Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
07:32

Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography

Published on: March 30, 2022

Serum matrix metalloproteinase-3 levels are elevated in myasthenia gravis

Fredrik R Romi1, Nils Erik Gilhus, Steven P Luckman

  • 1Department of Neurology, Haukeland University Hospital, N5021 Bergen, Norway.

Journal of Neuroimmunology
|February 12, 2008
PubMed

Insights

Matrix metalloproteinase-3 (MMP-3) may contribute to myasthenia gravis (MG) by degrading agrin, a key protein in neuromuscular signaling. Elevated MMP-3 levels were found in a subset of MG patients, suggesting a pathogenic role.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Immunology

Background:

  • Matrix metalloproteinase-3 (MMP-3) degrades proteins crucial for neuromuscular signaling, such as agrin.
  • Agrin is essential for acetylcholine receptor clustering at the neuromuscular junction.
  • Disruption of neuromuscular signaling can lead to muscle weakness and failure of neuromuscular transmission.

Purpose of the Study:

  • To investigate the role of MMP-3 in the pathogenesis of myasthenia gravis (MG).
  • To determine if MMP-3 levels are elevated in MG patients compared to healthy controls.

Main Methods:

  • Quantification of MMP-3 levels in serum samples from 116 MG patients (seropositive and seronegative) and 90 healthy controls.
  • Statistical analysis to compare MMP-3 levels between groups.

Main Results:

  • A significant elevation in MMP-3 levels was observed in a proportion of MG patients.
  • Elevated MMP-3 was detected in 10% of seronegative MG patients and 17% of seropositive MG patients.
  • These findings suggest a potential link between MMP-3 and MG pathophysiology.

Conclusions:

  • MMP-3 may play a pathogenic role in a subset of myasthenia gravis patients.
  • The degradation of agrin by MMP-3 could contribute to neuromuscular junction dysfunction in MG.
  • Further research is warranted to elucidate the precise mechanisms and clinical implications of MMP-3 in MG.

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...